Freedom Broker Initiates Coverage On Arcturus Therapeutics with Buy Rating, Announces Price Target of $27

Benzinga Newsdesk www.benzinga.com Neutral 57.1%

Neg 0% Neu 57.1% Pos 0%

Freedom Broker analyst Ilya Zubkov initiates coverage on Arcturus Therapeutics (NASDAQ:ARCT) with a Buy rating and announces Price Target of $27.